William Blair Has Negative Estimate for LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Investment analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Monday, December 16th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous estimate of ($0.32). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.16) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.81) EPS, FY2027 earnings at ($1.83) EPS and FY2028 earnings at ($0.19) EPS.

Several other research analysts have also commented on LRMR. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Larimar Therapeutics in a research report on Monday. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Robert W. Baird initiated coverage on shares of Larimar Therapeutics in a report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price objective for the company. Wedbush started coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Oppenheimer started coverage on Larimar Therapeutics in a report on Wednesday, October 16th. They set an “outperform” rating and a $26.00 target price on the stock. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Larimar Therapeutics currently has an average rating of “Buy” and an average price target of $20.43.

Larimar Therapeutics Trading Down 4.3 %

Shares of NASDAQ:LRMR opened at $3.98 on Thursday. The firm has a market cap of $253.95 million, a PE ratio of -3.46 and a beta of 0.86. The company has a fifty day simple moving average of $6.97 and a 200 day simple moving average of $7.65. Larimar Therapeutics has a 12-month low of $3.01 and a 12-month high of $13.68.

Larimar Therapeutics (NASDAQ:LRMR) last announced its earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same period in the previous year, the business earned ($0.21) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LRMR. Quarry LP increased its stake in shares of Larimar Therapeutics by 966.7% in the second quarter. Quarry LP now owns 8,000 shares of the company’s stock worth $58,000 after acquiring an additional 7,250 shares during the last quarter. Quest Partners LLC lifted its holdings in Larimar Therapeutics by 171.1% in the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after purchasing an additional 5,796 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Larimar Therapeutics during the 3rd quarter worth $71,000. Intech Investment Management LLC acquired a new position in Larimar Therapeutics in the 3rd quarter valued at $85,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Larimar Therapeutics in the third quarter valued at about $94,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.